毒结清口服液联合化疗治疗多发性骨髓瘤骨病临床研究

Effect of Dujieqing Oral Liquid Combined with Chemotherapy in Treatment of Osteolytic Lesions in Multiple Myeloma

目的:探讨以毒结清口服液治疗多发性骨髓瘤(MM)患者骨病的临床疗效。方法:将42例MM患者随机分成两组,对照组20例予M2方案化疗,中药组22例予中药毒结清口服液60mL/d,同时予M2方案化疗。以血钙和白介素-6(IL-6)水平下降,骨痛的缓解和生活质量改善为评价指标。结果:中药组和对照组治疗后骨痛症状评分均明显下降,与治疗前比较差异均有显著性意义(P<0.05);中药组生活质量总有效率为68.2%,与对照组总有效率(45%)比较差异均有显著性意义(P<0.05);中药组治疗后血钙和IL-6水平均明显下降(P<0.05),与对照组治疗后血钙和IL-6水平比较差异也有显著性意义(P<0.05);对照组治疗后血钙水平较治疗前有下降(P>0.05)。结论:毒结清口服液联合化疗能有效降低MM患者血钙和IL-6水平,改善骨痛症状,提高生活质量。

Objective：To observe the effects of Dujieqing Oral Liquid in combination with M2 regimen chemotherapy on patients with osteolytic lesions in Multiple Myeloma（MM）.Methods：Forty-two patients were randomized into two groups：control group（20 pts）were treated with M2 regimen chemotherapy only;in addition to M2 regimen Chemotherapy,TCM group（22 pts）were treated with Dujieqing Oral Liquid.Results：Scores of bone ache in TCM group and group control were lower than pretherapy（P〈0.05）.Total effective rate of life quality in TCM group was higher than that in control group（P〈0.05）.Blood calcium and IL-6 level in TCM group were lower than those in control group（P〈0.05）.Conclusion：Dujieqing Oral Liquid combined with chemotherapy can degrade blood calcium and IL-6 level and improve symptom of bone ache and quality of life.